Cathy Eng, MD
Recent clinical findings across gastrointestinal (GI) cancers addressed unanswered questions in a number of patient populations, said Cathy Eng, MD.
Furthermore, the ADORE trial provided data in the locally advanced rectal cancer setting. The study tested the addition of adjuvant oxaliplatin to leucovorin and 5-fluorouracil (5-FU; FOLFOX) versus leucovorin/5-FU alone. The primary endpoint of disease-free survival suggested a clear benefit with the addition of oxaliplatin.
... to read the full story